Affiliation:
1. Chuvash State University named after I.N. Ulyanova, Cheboksary
2. S.M. Kirov Military Medical Academy, Ministry of Defense of Russia, Saint Petersburg
Abstract
Objective. Study the reaction of the white pulp of the spleen of laboratory mice in an experiment on parenteral administration of human pharmacy albumin. Materials and methods. Nine 30-day-old mice were divided into three groups of three mice each (intact and two experimental). Experimental mice were intraperitoneally injected with a human albumin pharmacy drug at a dose of 0.9 ml every other day for 30 days. The animals of the intact and first experimental groups were removed from the experiment by decapitation on the 30th day from the beginning of the experiment, the second experimental group – 1 month after the last injection (60 days from the beginning of the experiment). Results. Albumin increased the wet mass of the spleen from 0.74±0.01 g (control) to 1.40±0.02 and 1.20±0.04 g in groups 1 and 2, respectively; induced amyloidosis, determined by the relative area of the congophilic substance in 4 microns of paraffin sections of the spleen – 13.32±1.31 and 23.47±0.84% in groups 1 and 2, respectively; reduced the average area of lymphoid nodules from 1.34±0.10•105 mkm2 (control) to 1.18±0.08•105 and 0.91±0.04•105 mkm2 in groups 1 and 2, respectively; increased the relative area of white pulp – from 22.65±2.30% (control) to 34.99±2.34 and 31.87±1.68% in groups 1 and 2, respectively, and reduced the relative area of the red pulp – from 77.35±4.20% (control) to 65.01±2.34 and 68.13±1.68% in groups 1 and 2, respectively, which led to a significant decrease in the index (red pulp) / (white pulp) from 6.67±1.39 (control) to 2.79±0.42 and 2.65±0.29 in groups 1 and 2, respectively. In all cases, the differences are statistically significant. Conclusions. Parenteral administration of human albumin to mice at a dose of 0.9 ml of a pharmacy drug causes amyloid damage to the spleen. Discontinuation of the introduction of amyloidogen protein does not prevent the development of the amyloid process that has begun.
Publisher
Russian Vrach, Publishing House Ltd.
Reference20 articles.
1. Габуева А.А., Козырев К.М., Брин В.Б. Способ моделирования экспериментального амилоидоза у животных. Патент на изобретение RU 2373581(51) МПК G09B23/28, 20.11.2009. Заявка № 2008128201/14 от 10.07.2008 [Gabueva A.A., Kozyrev K.M., Brin V.B. A method for modeling experimental amyloidosis in animals. Patent RUS no 2373581(51) MPK G09B23/28, 2009 (in Russ.)].
2. Călugăru A., Zamfir G., Onică D. Antibodies from patients with liver diseases and from normal human or animal sera against glutaraldehyde-polymerized albumins: lack of species specificity. Experientia. 1983; 39 (10): 1139–41. DOI: 10.1007/BF01943149
3. Sipe J.D., Benson M.D., Buxbaum J.N. et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010; 17 (3-4): 101–4. DOI: 10.3109/13506129.2010.526812
4. Taboada P., Barbosa S., Castro E. et al. Amyloid Fibril Formation and other Aggregate Species Formed by Human Serum Albumin Association. J Phys Chem B. 2006; 110 (42): 20733–6. DOI: 10.1021/jp064861r
5. Ilyina L.Y., Kozlov V.A., Sapozhnikov S.P. Мegakaryocytes of the spleen in experimental amyloidosis and effect of red wine. Bull Exp Biol Med. 2022; 172 (5): 598–601. DOI: 10.1007/s10517-022-05437-y